Evaluation of the Efficacy of Hippotherapy for Children With Developmental Disorders

Autism Spectrum Disorder Clinical Trial

Official title:

Evaluation of the Efficacy of Hippotherapy for Children With Developmental Disorders

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00717392
• Other study ID #: SHEBA-08-5327-LG-CTIL
• Status: Completed
• Phase: N/A
• First received: July 16, 2008
• Last updated: February 28, 2013
• Start date: September 2008
• Est. completion date: July 2012

Study information

• Verified date: February 2013
• Source: Sheba Medical Center
• Contact: n/a
• Is FDA regulated: No
• Health authority: Israel: Israeli Health Ministry Pharmaceutical Administration
• Study type: Observational

Clinical Trial Summary

Hippotherapy is every program of horseback riding meant to treat people with physiological, mental, social, cognitive or behavioral problems. The purpose of the current research is to evaluate the efficacy of hippotherapy for children with developmental disabilities. The hypothesis is that children with developmental disabilities who are treated with hippotherapy will show better outcomes than children with the same problems who are not treated with hippotherapy.

Description:

Hippotherapy is every program of horseback riding meant to treat people with physiological, mental, social, cognitive or behavioral problems. Most studies that tested hippotherapy were uncontrolled and focused on motor problems, such as cerebral palsy. Today, hippotherapy is used for various developmental problems such as Attention deficit / Hyperactivity disorder (ADHD) and Autism spectrum disorder (ASD), without clear information about its efficacy for these populations.

The purpose of the current research is to evaluate the efficacy of 6 months of hippotherapy for children with developmental disabilities. The hypothesis is that children with developmental disabilities who are treated with hippotherapy for 6 months will show better outcomes than children with the same problems who are not treated with hippotherapy.

Assessment:

• BRIEF questionnaire

• Stony Brook Questionnaire

All questionnaires will be applied at the beginning of the study and after 6 months.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 40
• Est. completion date: July 2012
• Est. primary completion date: June 2011
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 5 Years to 17 Years

Eligibility

Inclusion Criteria:

• Age: 5-17 years.

• A diagnosis of ADHD or ASD.

Exclusion Criteria:

Study Design

Time Perspective: Prospective

Related Conditions & MeSH terms

• Attention Deficit Disorder with Hyperactivity
• Attention Deficit Hyperactivity Disorder
• Autism Spectrum Disorder
• Child Development Disorders, Pervasive
• Developmental Disabilities
• Disease

Locations

Country	Name	City	State
Israel	Weinberg Child Development Center, Sheba Medical Center, Tel-Hashomer	Ramat-Gan

Sponsors (1)

Lead Sponsor	Collaborator
Sheba Medical Center

Country where clinical trial is conducted

Israel, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Improving the parameters of autism	Repetitive behaviors Eye contact Communication	Repetitive behaviors	No